The reality of modeling irritable bowel syndrome: progress and challenges.

IF 4.9 2区 医学 Q1 PHARMACOLOGY & PHARMACY Expert Opinion on Drug Discovery Pub Date : 2025-04-01 Epub Date: 2025-03-31 DOI:10.1080/17460441.2025.2481264
Maryam S Fakhri Bafghi, Niloofar Khoshnam Rad, Ghazal Roostaei, Shekoufeh Nikfar, Mohammad Abdollahi
{"title":"The reality of modeling irritable bowel syndrome: progress and challenges.","authors":"Maryam S Fakhri Bafghi, Niloofar Khoshnam Rad, Ghazal Roostaei, Shekoufeh Nikfar, Mohammad Abdollahi","doi":"10.1080/17460441.2025.2481264","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Irritable bowel syndrome (IBS) is a common gastrointestinal disorder that is often therapeutically challenging. While research has advanced our understanding of IBS pathophysiology, developing precise models to predict drug response and treatment outcomes remains a significant hurdle.</p><p><strong>Areas covered: </strong>This perspective provides an overview of the use of animal models alongside cutting-edge technologies used to bring drugs from bench to bedside.Furthermore, the authors examine the progress and limitations of IBS modeling. The authors further discuss the challenges of traditional animal models and gives a spotlight to the potential of innovative technologies, such as organ-on-chip systems, computational models, and artificial intelligence (AI). These approaches intend to enhance both the understanding and treatment of IBS.</p><p><strong>Expert opinion: </strong>Although animal models have been central to understanding IBS research, they have limitations. The future of IBS research resides in integrating organ-on-chip systems and utilizing modern technological developments, such as AI. These tools will enable the design of more effective treatment strategies and improve patients' overall well-being. To achieve this, collaboration between experts from various disciplines is essential to improve these models and guarantee their clinical application and reliability.</p>","PeriodicalId":12267,"journal":{"name":"Expert Opinion on Drug Discovery","volume":"20 4","pages":"433-445"},"PeriodicalIF":4.9000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Drug Discovery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17460441.2025.2481264","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/31 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Irritable bowel syndrome (IBS) is a common gastrointestinal disorder that is often therapeutically challenging. While research has advanced our understanding of IBS pathophysiology, developing precise models to predict drug response and treatment outcomes remains a significant hurdle.

Areas covered: This perspective provides an overview of the use of animal models alongside cutting-edge technologies used to bring drugs from bench to bedside.Furthermore, the authors examine the progress and limitations of IBS modeling. The authors further discuss the challenges of traditional animal models and gives a spotlight to the potential of innovative technologies, such as organ-on-chip systems, computational models, and artificial intelligence (AI). These approaches intend to enhance both the understanding and treatment of IBS.

Expert opinion: Although animal models have been central to understanding IBS research, they have limitations. The future of IBS research resides in integrating organ-on-chip systems and utilizing modern technological developments, such as AI. These tools will enable the design of more effective treatment strategies and improve patients' overall well-being. To achieve this, collaboration between experts from various disciplines is essential to improve these models and guarantee their clinical application and reliability.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
模拟肠易激综合征的现实:进展和挑战。
肠易激综合征(IBS)是一种常见的胃肠道疾病,通常具有治疗挑战性。虽然研究提高了我们对肠易激综合征病理生理学的理解,但开发精确的模型来预测药物反应和治疗结果仍然是一个重大障碍。涵盖领域:该视角概述了动物模型的使用以及用于将药物从实验室带到床边的尖端技术。此外,作者还研究了IBS模型的进展和局限性。作者进一步讨论了传统动物模型的挑战,并强调了创新技术的潜力,如器官芯片系统、计算模型和人工智能(AI)。这些方法旨在提高对肠易激综合征的认识和治疗。专家意见:虽然动物模型是理解肠易激综合征研究的核心,但它们有局限性。IBS研究的未来在于整合器官芯片系统和利用现代技术发展,如人工智能。这些工具将有助于设计更有效的治疗策略,并改善患者的整体健康状况。为了实现这一目标,来自不同学科的专家之间的合作对于改进这些模型并保证其临床应用和可靠性至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
10.20
自引率
1.60%
发文量
78
审稿时长
6-12 weeks
期刊介绍: Expert Opinion on Drug Discovery (ISSN 1746-0441 [print], 1746-045X [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on novel technologies involved in the drug discovery process, leading to new leads and reduced attrition rates. Each article is structured to incorporate the author’s own expert opinion on the scope for future development. The Editors welcome: Reviews covering chemoinformatics; bioinformatics; assay development; novel screening technologies; in vitro/in vivo models; structure-based drug design; systems biology Drug Case Histories examining the steps involved in the preclinical and clinical development of a particular drug The audience consists of scientists and managers in the healthcare and pharmaceutical industry, academic pharmaceutical scientists and other closely related professionals looking to enhance the success of their drug candidates through optimisation at the preclinical level.
期刊最新文献
Small open reading frame-encoded peptides (SEPs) as hidden treasures: a review. E protein inhibitors and host-directed therapies in dengue virus infection: perspectives on combination and complementary antiviral strategies. Enhancing structural insights for advanced drug discovery by mitigating protein crystal damage. Protein crystallization strategies in structure-based drug design. In silico structural analysis of carbapenemase variants in Klebsiella pneumoniae: insights for precision drug discovery against multidrug-resistant strains.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1